Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial

医学 临床终点 养生 内科学 危险系数 置信区间 随机对照试验 不利影响 病毒载量 胃肠病学 免疫学 病毒
作者
Anthony Raymond Tam,Ricky Ruiqi Zhang,Kwok Cheung Lung,Raymond W. Liu,Ka Nang Leung,Danlei Liu,Yu-Jing Fan,Lu Lu,Athene Hoi Ying Lam,Tom Wai-Hin Chung,Cyril C. Y. Yip,Jenny Lo,Alan H.B. Wu,Rodney A. Lee,Simon Sin,Pauline C. Ng,Wai Kin Chan,Hoi-Ping Shum,Wing-Wa Yan,Jasper Fuk-Woo Chan,Vincent C.C. Cheng,Chak Sing Lau,Kelvin Kai-Wang,Kwok-Hung Chan,Kwok-Yung Yuen,Ivan Hung
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
被引量:5
标识
DOI:10.1093/cid/ciac523
摘要

Abstract Background Early antiviral therapy was effective in the treatment of coronavirus disease 2019 (COVID-19). We assessed the efficacy and safety of combined interferon beta-1b and remdesivir treatment in hospitalized COVID-19 patients. Methods We conducted a multicentre, prospective open-label, randomized-controlled trial involving high-risk adults hospitalized for COVID-19. Patients were randomly assigned to a 5-day interferon beta-1b 16 million units daily and remdesivir 200 mg loading on day 1 followed by 100 mg daily on day 2 to 5 (combination group), or to remdesivir only of similar regimen (control group) (1:1). The primary endpoint was the time to complete alleviation of symptoms (NEWS2 = 0). Results Two-hundred and twelve patients were enrolled. The median days of starting treatment from symptom onset was 3 days. The median age was 65 years, and 159 patients (75%) had chronic disease. The baseline demographics were similar. There was no mortality. For the primary endpoint, the combination group was significantly quicker to NEWS2 = 0 (4 vs 6.5 days; hazard ratio [HR], 6.59; 95% confidence interval [CI], 6.1–7.09; P < .0001) when compared to the control group. For the secondary endpoints, the combination group was quicker to negative nasopharyngeal swab (NPS) viral load (VL) (6 vs 8 days; HR, 8.16; 95% CI, 7.79–8.52; P < .0001) and to develop seropositive immunoglobulin G (IgG) (8 vs 10 days; HR, 10.78; 95% CI, 9.98–11.58; P < .0001). All adverse events resolved upon follow-up. Combination group (HR, 4.1 95% CI, 1.9–8.6, P < .0001) was the most significant independent factor associated with NEWS2 = 0 on day 4. Conclusions Early treatment with interferon beta-1b and remdesivir was safe and better than remdesivir only in alleviating symptoms, and in shortening viral shedding and hospitalization with earlier seropositivity in high-risk COVID-19 patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JL发布了新的文献求助10
刚刚
刚刚
77完成签到,获得积分10
2秒前
李军发布了新的文献求助30
2秒前
2秒前
3秒前
3秒前
muzi871203完成签到,获得积分10
4秒前
全菌的DEPC水完成签到,获得积分10
4秒前
5秒前
daidaimumu发布了新的文献求助10
5秒前
5秒前
鸣笛应助枫1538采纳,获得50
6秒前
大洁发布了新的文献求助10
6秒前
JL完成签到,获得积分10
7秒前
zjw1997发布了新的文献求助30
7秒前
Lucas应助SUnnnnn采纳,获得10
8秒前
9秒前
胖心怡完成签到,获得积分10
10秒前
11秒前
goenkrrj完成签到,获得积分10
11秒前
11秒前
chun发布了新的文献求助10
11秒前
zyl发布了新的文献求助10
12秒前
12秒前
12秒前
吕创坤完成签到,获得积分10
13秒前
tt发布了新的文献求助10
14秒前
wh完成签到,获得积分10
14秒前
14秒前
goenkrrj发布了新的文献求助10
14秒前
keyaner发布了新的文献求助10
15秒前
Liskiat2021完成签到,获得积分10
15秒前
YamDaamCaa应助N0V1CE采纳,获得50
15秒前
airslake完成签到,获得积分10
16秒前
怡然映之完成签到,获得积分10
17秒前
poppy发布了新的文献求助10
17秒前
ScholarZmm完成签到,获得积分10
17秒前
Liskiat2021发布了新的文献求助10
18秒前
斯文败类应助zyl采纳,获得10
20秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969917
求助须知:如何正确求助?哪些是违规求助? 3514626
关于积分的说明 11175060
捐赠科研通 3249928
什么是DOI,文献DOI怎么找? 1795165
邀请新用户注册赠送积分活动 875617
科研通“疑难数据库(出版商)”最低求助积分说明 804891